摘要
目的观察米格列醇+格列吡嗪治疗2型糖尿病(T2DM)患者的临床疗效及对血糖水平的影响。方法将我院2022年1月至2023年1月收治的100例T2DM患者纳入研究,采用计算机系统随机分为格列吡嗪组(50例,格列吡嗪口服治疗)和联用组(50例,米格列醇+格列吡嗪治疗)。对比两组患者治疗前后的血糖水平[空腹血糖(FPG)、餐后2 h血糖(2 hPG)、糖化血红蛋白(HbA1c)]、胰岛功能指标[空腹胰岛素(FINS)、C肽(C-P)、胰岛素抵抗指数(HOMA-IR)]和药物不良反应情况,统计两组血糖达标率。结果治疗后,联用组的FPG、2 hPG、HbA1c均低于格列吡嗪组(P<0.05),联用组血糖达标率高于格列吡嗪组(P<0.05);治疗后,联用组的C-P、FINS高于格列吡嗪组,HOMA-IR低于格列吡嗪组(P<0.05);联用组的不良反应发生率与格列吡嗪组相比差异不大(P>0.05)。结论米格列醇+格列吡嗪治疗T2DM可显著下调患者的血糖水平指标,提升血糖达标率,有助于改善胰岛功能指标,未明显增加不良反应,安全性有保障。
Objective To observe the clinical efficacy of miglitol and glipizide in the treatment of type 2 diabetes mellitus(T2DM)and its effect on blood glucose level.Methods 100 T2DM patients admitted to our hospital from January 2022 to January 2023 were included in the study,and were randomly divided into glipizide group(50 cases,glipizide oral treatment)and combined group(50 cases,glipizide combined with miglitol treatment)by computer system.Blood glucose levels[fasting blood glucose(FPG),2 h postprandial blood glucose(2 hPG),glycosylated hemoglobin(HbA1c)],islet function indexes[fasting insulin(FINS),C-peptide(C-P),insulin resistance index(HOMA-IR)]and adverse drug reactions of the two groups were compared before and after treatment,and the blood glucose compliance rate of the two groups was statistically analyzed.Results After treatment,the FPG,2 hPG and HbA1c of combined group were lower than those of glipizide group(P<0.05),and the blood glucose compliance rate of combined group was higher than that of glipizide group(P<0.05).After treatment,C-P and FINS in combined group were higher than those in glipizide group,and HOMA-IR was lower than that in glipizide group(P<0.05).The incidence of adverse reactions in combination group was not significantly different from that in glipizide group(P>0.05).Conclusions Miglitol+glipizide in the treatment of T2DM can significantly reduce the blood glucose level index,improve the blood glucose compliance rate,and help improve the islet function index,without significantly increasing adverse reactions,and the safety is guaranteed.
作者
姚思丹
YAO Sidan(Zini Health Center,Longhai District,Zhangzhou City,Zhangzhou 363100,China)
出处
《中国医药指南》
2023年第36期81-83,87,共4页
Guide of China Medicine
